<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Mito Laboratories — Pipeline</title>
  <meta name="description" content="Early-stage pipeline at Mito Laboratories: mitochondria-centric programs advancing through discovery with a protocolised development approach." />
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
<a class="skip-link" href="#main">Skip to content</a>
<header class="site-header">
  <div class="nav-shell">
    <a class="brand" href="index.html">
      <div class="brand-mark" aria-hidden="true"></div>
      <div class="brand-name">
        <strong>MITO LABORATORIES</strong>
        <span>Protocolised mitochondrial biology</span>
      </div>
    </a>

    <button class="nav-toggle" type="button" data-nav-toggle aria-expanded="false" aria-controls="primary-nav">
      Menu
    </button>

    <nav id="primary-nav" class="nav-links" data-nav-links aria-label="Primary navigation">
      <a class="nav-link" href="index.html">Home</a>

      <!-- Our Company dropdown (hover) -->
      <div class="nav-item has-dropdown">
        <a class="nav-link" href="company-about.html">
          Our Company <span class="chev" aria-hidden="true"></span>
        </a>

        <div class="dropdown" id="company-menu" role="menu" aria-label="Our Company">
          <a class="dropdown-link" role="menuitem" href="company-about.html" aria-current="page">About us</a>
          <a class="dropdown-link" role="menuitem" href="company-team.html">Meet our team</a>
          <a class="dropdown-link" role="menuitem" href="company-news.html">News &amp; Events</a>
        </div>
      </div>

      <!-- Science dropdown (hover) -->
      <div class="nav-item has-dropdown">
        <a class="nav-link" href="science.html">
          Science <span class="chev" aria-hidden="true"></span>
        </a>

        <div class="dropdown" role="menu" aria-label="Science">
          <a class="dropdown-link" role="menuitem" href="pipeline.html">Pipeline</a>
          <a class="dropdown-link" role="menuitem" href="science.html">Philosophy</a>
          <a class="dropdown-link" role="menuitem" href="disease-focus.html">Disease focus</a>
        </div>
      </div>

      <a class="nav-link nav-cta" href="mailto:info@mitolaboratories.com">Contact</a>
    </nav>
  </div>
</header>


<main id="main">
  <section class="hero">
    <div class="container hero-grid">
      <div>
        <div class="kicker"><b>Pipeline</b> · discovery-stage portfolio</div>
        <h1>Multiple discovery tracks built on a mitochondria-centric platform.</h1>
        <p>
          Our pipeline is structured as a set of discovery programs targeting mitochondrial and metabolic control points.
          We advance candidates through screening, confirmation, and optimisation using a protocolised, measurement-first approach.
        </p>
        <div class="btn-row">
          <a class="btn primary" href="science.html">Platform &amp; mechanism</a>
          <a class="btn" href="disease-focus.html">Disease focus</a>
        </div>
      </div>

      <aside class="hero-card">
        <div class="hero-img" style="background-image:url('assets/hero-pipeline.svg')"></div>
        <div class="hero-meta">
          <h3 style="margin:0 0 8px;font-size:16px;">How to read the pipeline</h3>
          <ul class="list">
            <li>All programs currently in Discovery</li>
            <li>Milestones are assay- and biomarker-driven</li>
            <li>Optionality: internal discovery + external assets</li>
          </ul>
        </div>
      </aside>
    </div>
  </section>

  <section class="section">
    <div class="container">
      <h2>Pipeline overview</h2>
      <p>
        The pipeline below presents our current discovery-stage target classes. Each track is advanced via high-throughput
        screening (HTS), hit confirmation, and a defined optimisation path toward translational readouts and program selection.
      </p>

      <div class="card" style="padding:16px;">
        <img
          src="assets/pipeline-chart.svg"
          alt="Mito Laboratories pipeline chart showing discovery, preclinical, Phase 1, Phase 2, and Phase 3 columns. All current programs are positioned in the discovery column."
          style="width:100%;height:auto;border-radius:16px;border:1px solid rgba(255,255,255,.12);background:rgba(255,255,255,.03);"
        />
        <p style="margin:12px 0 0;color:var(--muted);font-size:13px;">
          Illustrative representation of development stages. Program naming, indication selection, and staging will be refined as data emerge.
        </p>
      </div>

      <hr class="hr" />

      <h2>Discovery tracks</h2>
      <p>
        These target classes reflect mitochondrial and metabolic control points that may create leverage in difficult-to-treat disease biology.
        Each track is milestone-gated and designed to generate decision-quality data early.
      </p>

      <div class="grid-3">
        <div class="card">
          <h3>Bcl-2 inhibition</h3>
          <p>Modulate apoptotic priming and survival dependency in relevant tumour contexts.</p>
        </div>
        <div class="card">
          <h3>MCT-1 inhibition</h3>
          <p>Disrupt lactate export and metabolic coupling in glycolysis-dominant settings.</p>
        </div>
        <div class="card">
          <h3>Lactate dehydrogenase inhibition</h3>
          <p>Reduce glycolytic throughput where lactate production sustains tumour fitness.</p>
        </div>
        <div class="card">
          <h3>Pyruvate dehydrogenase kinase inhibition</h3>
          <p>Shift flux toward oxidative metabolism and re-balance mitochondrial function.</p>
        </div>
        <div class="card">
          <h3>AMPK activation / mTOR inhibition</h3>
          <p>Recalibrate energy sensing and growth signalling with biomarker-guided dosing logic.</p>
        </div>
        <div class="card">
          <h3>Acidosis modulation</h3>
          <p>Target pH-linked invasion and immune suppression within the tumour microenvironment.</p>
        </div>
        <div class="card">
          <h3>Immune activation</h3>
          <p>Support immune engagement in settings where metabolism constrains immune function.</p>
        </div>
        <div class="card">
          <h3>Antimicrobial</h3>
          <p>Where relevant, address microbial contributions to inflammatory and oncogenic signalling.</p>
        </div>
        <div class="card">
          <h3>Mitochondrial repair</h3>
          <p>Restore bioenergetic integrity and signalling fidelity in stressed cellular environments.</p>
        </div>
      </div>

      <hr class="hr" />

      <h2>External asset strategy</h2>
      <p>
        In parallel with internal discovery, we will evaluate opportunities to acquire or in-license assets that were previously
        developed and later discontinued by industry. This can accelerate timelines when prior chemistry, safety, or translational
        learnings exist — provided the asset fits our mitochondria-centric hypothesis and can be advanced with a clear protocolised plan.
      </p>

      <div class="grid-3">
        <div class="card">
          <h3>What we look for</h3>
          <p>Mechanistic alignment, credible IP position, and actionable development path.</p>
        </div>
        <div class="card">
          <h3>What we verify</h3>
          <p>Reproducible biology, clean confirmation data, and practical PK/PD readouts.</p>
        </div>
        <div class="card">
          <h3>Why it matters</h3>
          <p>De-risk discovery while preserving optionality for fast-moving programs.</p>
        </div>
      </div>

      <hr class="hr" />

      <h2>Seed-stage milestones (template)</h2>
      <ul class="list">
        <li><strong>Assay build &amp; validation:</strong> functional readouts with reproducibility and counterscreens</li>
        <li><strong>HTS → hit confirmation:</strong> orthogonal validation and early mechanism-of-action evidence</li>
        <li><strong>Hit → lead criteria:</strong> potency, selectivity, cellular activity, and a translational biomarker plan</li>
        <li><strong>Program selection:</strong> prioritise 1–2 lead programs with decision-quality data</li>
      </ul>
    </div>
  </section>
</main>

<footer class="footer">
  <div class="container">© 2026 Mito Laboratories. All rights reserved.</div>
</footer>

<script src="script.js"></script>
</body>
</html>
